Allopurinol 100mg tablets

Țară: Regatul Unit

Limbă: engleză

Sursă: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredient activ:

Allopurinol

Disponibil de la:

Alliance Healthcare (Distribution) Ltd

Codul ATC:

M04AA01

INN (nume internaţional):

Allopurinol

Dozare:

100mg

Forma farmaceutică:

Oral tablet

Calea de administrare:

Oral

Clasă:

No Controlled Drug Status

Tip de prescriptie medicala:

Valid as a prescribable product

Rezumat produs:

BNF: 10010400

Prospect

PI Size : 280 mm x 240 mm
Color : Black
Font : 9 Pt.
Track : 19/07/2018, 01/08/2018, 24/09/2018
PACKAGE LEAFLET: INFORMATION FOR THE USER
ALLOPURINOL 100MG AND 300MG TABLETS
Allopurinol
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you. Do not pass it onto
others. It may harm them, even if their
symptoms are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not
listed in this leaflet (See section 4).
WHAT IS IN THIS LEAFLET:
1. What Allopurinol tablets is and what it is used for
2. What you need to know before you take Allopurinol Tablets
3. How to take Allopurinol Tablets
4. Possible side effects
5. How to store Allopurinol Tablets
6. Contents of the pack and other information
1. WHAT ALLOPURINOL TABLET IS AND WHAT IT IS USED FOR
These tablets contain Allopurinol and are available in strengths of
100mg and 300mg. Allopurinol works by
slowing down the speed of certain chemical reactions in your body.
Allopurinol is used to treat high levels of uric acid in the body,
which can cause gouty arthritis, skin and kidney
problems. Some people may not get any symptoms.
Allopurinol is also used to prevent and treat kidney stones in
patients who have high uric acid levels.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ALLOPURINOL TABLETS:
Serious skin rashes (Hypersensitivity syndrome, Stevens- Johnson
syndrome, toxic epidermal necrolysis)
have been reported with the use of allopurinol. Frequently, the rash
can involve ulcers of the mouth, throat,
nose, genitals and conjunctivitis (red and swollen eyes). These
serious skin rashes are often preceded by
influenza-like symptoms fever, headache, body ache (flu-like
symptoms). The rash may progress to
widespread blistering and peeling of the skin. These serious skin
re

Caracteristicilor produsului

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Allopurinol Tablets 100 mg
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Allopurinol 100 mg per tablet.
Excipient with known effect: Each tablet contains 180 mg lactose,
For the full list of excipients, see 6.1.
3
PHARMACEUTICAL FORM
Tablet.
Allopurinol Tablets 100 mg are presented as white, normal convex
tablets
engraved with the company logo on one side and A329 on the other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Allopurinol is indicated for reducing urate/uric acid formation in
conditions
where urate/uric acid deposition has already occurred (_e.g._ gouty
arthritis, skin
tophi, nephrolithiasis) or is a predictable clinical risk (_e.g._
treatment of
malignancy potentially leading to acute uric acid nephropathy). The
main
clinical conditions where urate/uric acid deposition may occur are:
idiopathic
gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic
disease and
myeloproliferative disease with high cell turnover rates, in which
high urate
levels occur either spontaneously, or after cytotoxic therapy; certain
enzyme
disorders which lead to over production of urate for example
hypoxanthine-
guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome;
glucose-6-phosphatase including glycogen storage disease;
phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate
amidotransferase; adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of 2,8-dihydroxyadenine
(2,8-
DHA) renal stones related to deficient activity of adenine
phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium
oxalate renal stones in the presence of hyperuricosuria, when fluid,
dietary and
similar measures have failed.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Adults _
Allopurinol should be introduced at low dosage e.g. 100 mg/day to
reduce the risk of
adverse reactions and increased only if the serum urate response is
unsatisfactory.
Extra caution should be ex